▎WuXi AppTec Content Team Report

Today (August 20th)Puzhong Discovery and ADCendo jointly announced that the two parties have reached an agreement on a project with the code name ADCE-T02 (Puzhong Discovery's R&D code AMT-754).Novel, Highly Differentiated Antibody-Drug Conjugate (ADC) Targeting Tissue Factor (Anti-TF)Under the licensing agreement, Adcendo will obtain exclusive global development and commercialization rights outside of Greater China, while Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. will retain the development and commercialization rights in Greater China (including mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan).

According to the financial terms of the agreement, Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. will receiveTens of millions of dollars in upfront payments, and will charge upon achieving subsequent development, regulatory, and commercial milestones.Totaling over 1 billion US dollarsTotal milestone payments, as well as single-digit to low double-digit percentage royalties based on global net sales (excluding Greater China).

Tissue Factor (TF) is overexpressed in bladder cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, esophageal cancer, head and neck cancer, and gastrointestinal cancer, but its expression is restricted in normal tissues, making it an excellent ADC target.

ADCE-T02 is a novel, highly differentiated anti-TF ADC whose unique antibody design can reduce the impact on the coagulation pathway. Meanwhile, the T1000-exatecan linker-payload technology platform has been proven by research.Capable of amplifying the "bystander effect," enhancing linker stability, and possessing the potential to overcome drug resistance mechanisms.. These differentiated characteristics are expected to translate into higher clinical treatment response rates, longer duration of efficacy, and better safety, offering a superior therapeutic window.

It is reported that ADCE-T02 has been submitted for clinical trial in Australia and is expected to file for U.S. IND in the near future.

ADCendo stated that TF is an excellent ADC target with tremendous potential in a wide range of indications with unmet needs. The highly differentiated design of ADCE-T02 can fully leverage the advantages of this target, with the potential to bring real benefits to more cancer patients.

Public information shows that Puzhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd. is a clinical-stage company focused on the development of ADC drugs, currently with several ADC pipelines under development, including three ADC pipelines targeting novel antigens. ADCendo ApS is dedicated to developing breakthrough antibody-drug conjugates (ADCs) for the treatment of rare cancers. In 2024, the company completed an extension of its Series A financing round, raising a total funding amount of 98 million euros to advance, expand, and accelerate the development of its novel antigen-targeted ADC pipelines.

[1Puzhong Discovery Pharmaceutical Technology(Shanghai) Co., Ltd. and ADCendo ApS Reach Development and Commercialization Collaboration for ADC Products. Retrieved Aug 20, 2024, from https://mp.weixin.qq.com/s/NDIJXekjc_XJD3T2DNgD8g